Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by KalVista Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.